Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Fever; This non-serious case was reported by a consumer via call center representative and described the occurrence of fever in a 59-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, less than a year after receiving Shingrix, the patient experienced fever (Verbatim: Fever). The outcome of the fever was unknown. It was unknown if the reporter considered the fever to be related to Shingrix. It was unknown if the company considered the fever to be related to Shingrix. Linked case(s) involving the same patient: US2025AMR079662 Additional Information: GSK Receipt Date: 24-JUN-2025 While asking questions about Shingrix, the caller mentioned that her daughter had a reaction to Shingrix. When questioned about this event, she was reluctant to provide any information, only saying that her daughter received both doses of Shingrix vaccine a few months ago in 2024 and that she had a fever in 2024 after the first dose. She did not wish to provide any further information on behalf of her daughter without her daughter's consent.